SK Bioscience Co., a bio and pharmaceutical affiliate of South Korea's SK Group, announced on Thursday that its world-first cell culture-based quadrivalent influenza vaccine SKYCellflu has received approval from the Instituto de Salud Publica de Chile (Chilean Institute of Public Health).
The company had previously obtained permission in Southeast Asia and the Middle East, including countries such as Malaysia and Thailand.
SK Bioscience plans to expand its global flu vaccine market into Central and South America with approval in Chile.
SKYCellflu has a shorter manufacturing period than traditional egg-based vaccines and has shown acceptable levels of immunogenicity and safety in clinical trials with over 1,500 adults and 453 children. The vaccine has also received pre-qualification from the World Health Organization.
Due to the COVID-19 pandemic, SK Bioscience temporarily suspended the manufacturing of SKYCellflu, but it will resume this year for the flu vaccination season.
"We will do our best to contribute public health beyond Korea to the world," said Ahn Jaeyong, CEO of SK Bioscience.
Write to Jung-Eun Kim at
likesmile@hankyung.com
